Key points – Patients with relapsed ALCL who achieved complete response with brentuximab vedotin had 79% overall survival and 57% progression free survival at 5 years, with median response duration not reached. An estimated 91% of patients who experienced peripheral neuropathy with brentuximab vedotin reported resolution or improvement of symptoms.
Home / Resource Library / Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma